MicroR-9-5p suppresses EV71 replication through targeting NFkB of the RIG-I-mediated innate immune response

Bing Li and Junqing Zheng
Department of Pediatrics, Jinan Maternity and Child Care Hospital, China

Keywords
EV71; inflammation; innate immunity; miR-9; NFkB

Correspondence
J. Zheng, Department of Pediatrics, Jinan Maternity and Child Care Hospital, No. 2 Jiaogong xiaojing san Road, Jinan, Shandong 250001, China
Tel: +86 18053153116
E-mail: zjqing16@163.com

Bing Li and Junqing Zheng contributed equally to this work and should be considered as equal first coauthors.

(Received 21 May 2018, accepted 25 June 2018)
doi:10.1002/2211-5463.12490

Accumulating evidence demonstrates that there is a causative link between hsa-microRNA-9-5p (miR-9) and pathophysiological processes. Enterovirus 71 (EV71) has been found to contribute to numerous severe clinical symptoms which result in death. The exact mechanism by which EV71 influences miR-9 expression is unknown, and the relationship between miR-9 and EV71 is still unclear. Here, miR-9 expression was found to be impaired upon EV71 infection in several cell lines and in an EV71 infection mouse model. Additionally, we confirmed that EV71 infection induces robust expression of pro-inflammatory cytokines (TNF-α, IL-6, and IL-1) and interferons (IFN-α and IFN-β). Overexpression of miR-9 attenuated EV71 proliferation and reduced protein and gene expressions of virion protein 1 (VP1) of EV71. Furthermore, we observed that the inflammation caused by EV71 infection was restored to a moderate level via miR-9 overexpression. Nuclear factor kappa B (NFkB) in the retinoic acid-induced gene 1 (RIG-I) signaling pathway, but not interferon regulating factor 3 (IRF3), was significantly decreased and inactivated by ectopic miR-9 expression. Moreover, in mouse infection experiments, administration of miR-9 agomirs caused a significant decrease in VP1 levels and pro-inflammatory cytokine production after viral inoculation. Taken together, the present data demonstrate that miR-9 exerts an anti-EV71 effect in cells and a mouse model via mediating NFkB activity of the RIG-I signal pathway, thereby suggesting a new candidate for antiviral drug development.

Hand, foot, and mouth disease (HFMD) is a viral infection commonly occurring in children and infants, which produces flu-like symptoms and blisters [1–3]. HFMD is caused by enteroviruses [e.g., coxsackievirus A16 and enterovirus 71 (EV71)] [4–6]. EV71 is a single-stranded positive-sense RNA virus belonging to the Enterovirus genus of the Picornaviridae family [7,8]. Infection by EV71 in children is related to severe neurological, pulmonary, and gastrointestinal dysfunctions. It has been suggested that disease severity is additionally affected by host factors, such as the host immune response [9]. The severity of EV71 infection has been found to be related to excessive and robust pro-inflammatory chemokine and cytokine responses and production [10].

The innate immune system affords defense against invading pathogens at an early phase of infection by

Abbreviations
BSA, bovine serum albumin; CARD, caspase-recruitment domain; DMEM, Dulbecco’s modified Eagle’s medium; EV71, enterovirus 71; FBS, fetal bovine serum; HEK, human embryonic kidney; HFMD, hand, foot, and mouth disease; IL, interleukin; IRF3, interferon regulating factor 3; miR-9, hsa-microRNA-9-5p; MOI, multiplicity of infection; NFkB, nuclear factor kappa B; PAMPs, pathogen-associated molecular patterns; PRR, pattern recognition receptor; RIG-I, retinoic acid-induced gene 1; RLR, RIG-I-like receptor; TLR, Toll-like receptor; TNF-α, tumor necrosis factor-alpha; VP1, virion protein 1.
recognizing various conserved pathogen-associated molecular patterns (PAMPs), including viral RNAs, and acting to limit virus replication. RLRs (RIG-I-like receptors) [11], TLRs (Toll-like receptors) [12], and NOD-like receptors [13] are members of PRRs (pattern recognition receptors), which can recognize viral RNA and elicit downstream signal transduction to provoke the innate immune response. Innate immunity is utilized by the host to fight against foreign pathogens, and EV71 invasion triggers the RLR and TLR pathways to counter the duplication and spreading of the virus. RIG-I, an essential receptor that recognizes EV71 RNA, engages in cytokine production in the host. RIG-I releases the N-terminal caspase-recruitment domain (CARD) for interaction with an identical domain on the adaptor protein located on the outer membrane of mitochondria after it interacts with viral RNAs [14], and consequently activates nuclear factor kappa B (NFκB) and interferon regulating factor 3/7 (IRF3/7). Phosphorylation of NFκB and IRF3/7 induces production of pro-inflammatory cytokines, chemokines, interferon (IFN), and adhesion molecules against pathogen invasion. However, the hyperinduction of pro-inflammatory cytokines induced by pathogenic infection, such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and IL-6 (i.e., a cytokine storm), causes complications or even ultimately death as a result of these infections [15].

The microRNAs (miRs) belong to a group of small noncoding RNAs, which were first identified in C. elegans in 1993 [16]. Previous reports demonstrated that miRs function in many pathological and biological processes, including inflammation and viral infection [17–22]. MicroRNAs additionally play an essential role in EV71 infection and modulating viral replication and pathogenicity [23–25]. In our study, we found that EV71 infection downregulated the expression of miR-9. Ectopic expression of miR-9 with EV71 infection induced an RLR-triggered innate immune response and pro-inflammatory cytokine production. Moreover, miR-9 agomirs were able to limit EV71 replication by maintaining cytokines at a moderate level in different tissues in animal model. Notably, our data reveal that miR-9 significantly decreased EV71-induced excessive production of pro-inflammatory cytokines through reducing expression and activation of NFκB. Given these results, our data demonstrate that miR-9 positively regulates inflammation elicited by EV71 and suppresses virus replication by targeting NFκB.

Materials and methods

Cell culture

Human embryonic kidney (HEK) 293T cells, human rhabdomyosarcoma cells (RD), human cervical carcinoma cells (HeLa), human colorectal cells (HT-29), Vero cells, and human monocytes (THP-1) were obtained from ATCC (Manassas, VA, USA) and maintained in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, Shanghai, China) supplemented with 2% penicillin/streptomycin and 10% (v/v) fetal bovine serum (FBS; Gibco) at 5% CO₂ and 37 °C. This work was approved by Jinan Maternity and Child Care Hospital.

Virus propagation

Enterovirus 71 (Shenzhen strain, GenBank accession number AF30299.1) infection was performed as follows. Vero cells were used to produce human EV71. Briefly, Vero cells were seeded into a dish prior to infection. EV71 was dispersed in DMEM, followed by inoculation to Vero cells (approximately 80% confluence). We added DMEM supplemented with 2% FBS, and the infection was allowed to proceed until the monolayer showed cytopathic effects (CPE). The culture medium and cells were harvested and subjected to three freeze-thaw cycles. Ten-minute centrifugation at 4500 g was performed, and the supernatant was transferred into cryovials and stored at ~80 °C.

The 50% tissue culture infectious dose titration

The 50% tissue culture infectious dose (TCID₅₀)/mL titration was determined for the virus as follows. Briefly, we seeded ~5000 RD cells/well in a 96-well plate. DMEM supplemented with FBS (2%; 10⁵ to 10⁸ dilution) was used to dilute the virus, and each dilution was added in separate wells. The plates underwent incubation at 5% CO₂ and 37 °C for 2 to 5 days. Using microscopy, CPE was analyzed. Reed–Münch endpoint calculation was employed to determine TCID₅₀.

EV71 infection

Enterovirus 71 infection of 293T, Vero, RD, HT-29, HeLa, and THP-1 cells was performed. Specifically, EV71 was inoculated into monolayer cells at approximately 50% confluence at a multiplicity of infection (MOI) of 1–10 TCID₅₀/cell. After 1 h of adsorption in an incubator at 37 °C and 5% CO₂, culture medium without FBS was used to wash the cells to remove free virus. Then, fresh culture medium supplemented with FBS (10%) was added. Cells were harvested for further examination at the indicated time points.

Animal infection models

Pregnant mice (ICR) were provided by Vital River (Beijing, China). All of the mice were raised in a pathogen-free room with separate ventilation cage systems. The mice were aged...
for two weeks and then were infected with either sterile PBS or EV71 at the dose of $10^5$ TCID$_{50}$/mouse via an intraperitoneal route. Disease manifestations and weight were observed and recorded every day following infection. The animals were sacrificed four or five days after posterior paralysis appeared. Muscle tissue, spleen, heart, lung, brain, kidney, small intestine, and whole blood were harvested, and RNA was extracted.

All experiments followed the institutional guidelines for animal research, and approval was obtained from the Ethics Committee of the Jinan Maternity and Child Care Hospital.

Antibodies

Anti-VP1 (from Shenzhen strain, bs-2297R), monoclonal anti-β-actin (ab8227), anti-RIG-I (sc-376845), anti-IL-1 (ab9722), anti-IFN-β (ab151605), and anti-NFkB (ab16502), anti-IRF3 (ab25950), anti-phospho-NFkB (ab86299), and anti-phospho-IRF3 (ab192796) antibodies were purchased from Abcam (CA, USA) and Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA) to detect the indicated protein by western blotting. Goat anti-rabbit IgG conjugated to TRITC (tetramethyl rhodamine isothiocyanate) secondary antibodies were purchased from Zhongshan Golden Bridge Biotechnology (Beijing, China) and was used for immunofluorescence assay (IFA).

Western blotting

Cells were lysed in RIPA buffer (pH 8.0, 50 mM Tris/HCl, 150 mM NaCl, 1% NP-40, 0.1% SDS) containing a protease inhibitor cocktail. The BCA Protein Quantitation Kit (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s instructions. The levels of mRNA were determined using SYBR Green Master Mix (4385618; Thermo Fisher Scientific) incorporation on a Roche LightCycler 480 Real-Time PCR system (Roche, Basel, Switzerland), and GAPDH was used as the internal control. The sequences of the primers used are shown in Table 1.

Quantitative real-time PCR was performed in 20 μL volumes using the SYBR Green PCR Master Mix in the LightCycler 480 with the following conditions: 95 °C for 10 min, then 40 cycles of 95 °C for 15 s, 60 °C for 30 s, and 72 °C for 30 s. The level of each mRNA (2$^{-ΔΔCT}$) was calculated through normalization to the endogenous reference and relative to the calibrator (the mean of the control samples).

Immunofluorescence assays

Virus infection of RD cells grown in 24-well plates with cover slides was performed at an MOI of 0.1 TCID$_{50}$/cell. Paraformaldehyde (4%) in PBS was used to fix the cells for 1 h at room temperature. Ten-minute permeabilization of the cells with PBST was performed at 25 °C, followed by a 1-h incubation with PBST (including 0.4% BSA) at 37 °C and a subsequent 1-h incubation with polyclonal anti-VP1 antibody, which was diluted in PBST (including 0.2% BSA) at 37 °C. Following a 1-h PBST wash, the cells underwent 1-h incubation with TRITC-labeled goat anti-rabbit antibody diluted in 0.2% BSA and PBST at 37 °C. Next, cells were washed for 1 h with PBST. DAPI was used to stain the

**Table 1. Primer sequences.**

| Full name | Abbreviation |
|-----------|--------------|
| miR-9 F   | 5'-GGT CTT TGG TTA TCT AGC TGT ATG A-3' |
| miR-9 R   | 5'-GGT CAG GGT CCG AGG T-3' |
| VP1 F     | 5'-GCT CTA TAG GAG ATA GTG TGA GTA GGG-3' |
| VP1 R     | 5'-ATG ACT GCT CAC CTG CGT GTT-3' |
| RIG-I F   | 5'-GGG GCT GGC AAA ACA AAT CAG-3' |
| RIG-I R   | 5'-GCA ATG TCA ATG CCT TCA TCA-3' |
| Human IL-1 F | 5'-TGA AAT GCC ACC TTT TTA CAG-3' |
| Human IL-1 R | 5'-CCA CAC CCA CAA TGA GTG ATA C-3' |
| Mouse IL-1 F | 5'-GCA CTA CAG GCT CCG AGA TGA AC-3' |
| Mouse IL-1 R | 5'-TTG TCG TTG CTT CTG TCT CAG-3' |
| IL-6 F    | 5'-TCC CTT GGG ACT GAT-3' |
| IL-6 R    | 5'-CGT GTG TTG TCT CTG T-3' |
| TNF-α F   | 5'-CGA GAT GCT TCA TCC GGC CA-3' |
| TNF-α R   | 5'-CCA GGT GAC TGG GTC AGC-3' |
| IFN-α F   | 5'-TAA TTC CTA CGT CCT TCT TT-3' |
| IFN-α R   | 5'-TAT TGC TCA TCG AAG AAT-3' |
| Human IFN-β F | 5'-TAG CAG TGG CTG GAA TGA GA-3' |
| Human IFN-β R | 5'-TCC TGG GCC TGG AGA TAA T-3' |
| Mouse IFN-β F | 5'-AAG ATG TAC ACT GCC TCC ATC-3' |
| Mouse IFN-β R | 5'-CAC TGT CTC GTG GAG TCG TAC-3' |
| GAPDH F   | 5'-GGG AAG CTG TGG CGT CTA-3' |
| GAPDH R   | 5'-AAG GTG GAA GAA TGG AGG T-3' |
nuclei of the cells. A confocal laser scanning fluorescence microscope (Olympus LSCM FV500, Olympus, Tokyo, Japan) was employed to analyze VP1 staining in cells.

miR-9-mimic and miR-9 agomir preparation

miR-9-mimic and a scramble control, NC-mimic, were purchased from Genscript (Shanghai, China). miR-9-mimic is an artificial, chemically modified double-stranded miRNA, which mimics the mature endogenous miR-9 after being transfected into cells with concentration of 100 μg·mL⁻¹. Both miR-9-mimic and NC-mimic were suspended in 0.9% NaCl to a final storage concentration of 10 mg·mL⁻¹.

The miR-9 agomir is a double-stranded RNA analog of mature miR-9 which has been chemically modified and conjugated to a cholesterol moiety to promote specificity and stability for assays. For treatment in vivo, agomiR-9 (RiboBio, Guangdong, China) was injected intravenously into the tail vein at a dose of 1 nmol (diluted in 20 μL PBS) per mouse three days before EV71 infection.

Bioinformatics analysis

The potential targets of miR-9 were identified by combining algorithms using miRDB (http://www.mirdb.org). The targets predicted by these algorithms were analyzed, and the candidates were selected according to the function.

Dual-luciferase reporter assay

Amplification of the 3′-UTR of the NFκB gene was performed, which was inserted into the GV126 luciferase gene. The binding sites for miR-9 on the NFκB gene were destroyed by mutagenesis, and the mutants were selected as controls. The transfection efficiency was adjusted by the thymidine kinase promoter (pRL-TK vector; TaKaRa, Beijing, China) and the Renilla luciferase gene, which contained the plasmid. Cotransfection of miR-9-mimic and NC-mimic into the luciferase reporter vector was conducted for different cell lines with Lipofectamine 2000 transfection reagent. The luciferase assay was performed according to the manufacturer’s instructions. Myellicin (to avoid any possibility of the fungal and/or bacterial infection during handling the experiments) was added into the cell culture in DMEM (supplemented with 10% FBS), followed by incubation at 5% CO₂ and 37 °C. The medium was changed every two days. Then, 0.25% trypsin was used to detach the cells, followed by subculture when the cells reached ~70–80% confluency.

Statistical analysis

The data are presented as the mean ± standard deviation. Two-tailed Student’s t-test was employed for comparison.

Values of P < 0.05 were considered statistically significant: *P < 0.05; **P < 0.01; and ***P < 0.001.

Results

miR-9 expression decreases during EV71 infection

The miR-9 expression in 293T, Vero, RD, HT-29, HeLa, and THP-1 cells was examined at 24 h after EV71 infection. Virion protein 1 (VP1) expression was found to be markedly increased in each of these six cell lines after EV71 infection at both the protein and mRNA levels (Fig. 1A,B), indicating the successful infection by EV71. We then found that miR-9 expression was significant decreased after EV71 infection in all cell lines, especially in RD cells. Next, EV71-infected mice were utilized to examine miR-9 expression in vivo. The EV71 was injected into the abdomen of the mice, which were sacrificed either four or five days following appearance of severe posterior paralysis. Real-time PCR analysis revealed that the virus mainly localized to the lung and muscle (Fig. 1C). There were relatively low titers of EV71 in the spleen, brain, liver, and intestine. The expression level of miR-9 in different tissues was then examined. We observed a significant decrease in miR-9 expression in muscle, intestine, lung, and brain (Fig. 1D). Taken together, these data demonstrate that EV71 mainly replicates in muscle. The downregulation of miR-9 in muscle induced by EV71 infection was verified by real-time PCR (Fig. 1E).

EV71 infection causes pro-inflammatory cytokine production

To confirm whether EV71 infection causes robust production of pro-inflammatory cytokines, real-time PCR and western blotting were conducted to assess the expression of IL-1, IL-6, TNF-α, IFN-β, and IFN-α at the protein and mRNA levels after EV71 infection of human colorectal, Vero, and rhabdomyosarcoma cells. As Fig. 2A shows, IL-1 and IFN-β expression in three cell lines was significantly increased in the EV71-infected group. Real-time PCR data further confirmed that IL-1, IL-6, TNF-α, IFN-α, and IFN-β mRNA levels were significantly elevated after EV71 infection, especially in RD cells (Fig. 2B). Next, the EV71-infected mouse model was utilized to evaluate relative IL-1 and IFN-α expression in several tissues. As expected, excessive production of cytokines was observed in muscle and lung tissue (Fig. 2C). These data clearly demonstrate that EV71 invasion induces pro-inflammatory cytokine production in vitro and in vivo.
Ectopic expression of miR-9 inhibits EV71 replication

After human colorectal, Vero, and rhabdomyosarcoma cells were infected with EV71 and/or transfected with miR-9-mimic, multiple growth curves were determined to assess the influence of miR-9 on EV71 replication. As shown in Fig. 3A, the viral growth rate was significantly reduced by 10²- to 10⁵-fold in miR-9-mimic-treated cells. The viral protein 1 (VP1) was examined at the protein and mRNA levels at the indicated time points. As shown in Fig. 3B, VP1 expression was significantly decreased by miR-9-mimic transfection, especially in RD cells, in which its expression pattern was markedly reduced. The decrease in viral protein was consistent with real-time PCR results, which showed that the mRNA level of VP1 was significantly reduced in the miR-9-mimic-treated group compared with the nontreated group (Fig. 3C). We then performed IFA to visualize the VP1 in the infected RD cells. As shown in Fig. 3D, the level of VP1 in EV71-infected cells treated with miR-9-mimic was significantly less than that in the nontreated group. These results suggest that miR-9 significantly decreased the viral titers of EV71 in different cell lines.

miR-9 inhibits excessive production of pro-inflammatory cytokines induced by EV71

To confirm the effect of miR-9 on pro-inflammatory cytokine production at the cellular level, real-time
PCR was performed to evaluate the level of cytokines and interferon. Importantly, we found that three essential cytokines in EV71-infected cells, IL-1, IL-6, and TNF-α, were gradually induced at different stages of infectious cycle. However, their expressions were kept at a moderate level at the examined time points postinfection in the miR-9-mimic-treated group (Fig. 4A). Furthermore, these cytokines in RD cells were examined by western blotting. In the EV71-infected group, cytokine expression significantly increased, but their expression
Fig. 3. miR-9 attenuates the replication of EV71 replication. Vero, RD, and HT-29 cells were infected with EV71. (A) At the indicated time points, titers of the viruses in the culture supernatants were determined in Vero, RD, and HT-29 cells. Error bars represent the standard error of the mean from replicate samples. (B) The viral VP1 protein of EV71 was detected by western blotting at several time points during the first viral replication cycle (12, 24, and 36 h) in HT-29, Vero, and RD cells. (C) Real-time PCR was performed to detect VP1 expression of EV71 at different time points. (D) VP1 subcellular localization was examined by IFA after miR-9-mimic transfection and EV71 infection for 12 and 24 h. These assays have been performed three times. Data represent means ± SD. **P < 0.01. The statistical test performed using Student’s t-test.
production was clearly suppressed by miR-9 expression (Fig. 4B). These results indicate that miR-9 ameliorated the robust cytokine storm induced by EV71 at the later stage of infection.

Enterovirus 71 viral infection can induce multiple innate immune signaling pathways, especially the RIG-I-like receptor (RLR) pathway. To determine whether the RIG-I pathway plays an essential role in the miR-9-regulated host innate immune response to EV71 infection, analysis of RIG-I and two key sensors (IRF3 and NFκB) was performed at the transcriptional and translational levels after EV71 infection and/or miR-9-mimic treatment (Fig. 5A). Protein expression of both IRF3 and RIG-I in miR-9-mimic-expressing cells did not show a significant difference with nontransfected cells. However, NFκB expression decreased after miR-9-mimic transfection compared to cells only induced by EV71. Additionally, phosphorylated NFκB, which is an indication of activated NFκB, was reduced, but phosphorylated IRF3 was not.

Fig. 4. miR-9-mimic transfection suppresses pro-inflammatory cytokine production in EV71-infected cells. RD cells were transfected with miR-9-mimic and then infected with EV71 at 24 h postinfection. The expression of pro-inflammatory cytokines IL-1, IL-6, TNF-α, IFN-α, and IFN-β of infected cells was examined by (A) real-time PCR and (B) western blotting at several time points. These assays have been performed three times. Data represent means ± SD. *P < 0.05; **P < 0.01; ***P < 0.001. The statistical test performed using Student’s t-test.
Consistent with these results, real-time PCR data suggested more efficient downregulation of NFκB was observed in RD cells treated with miR-9-mimic, while lower NFκB was detected in the miR-9-mimic-treated group, compared to the nontreated group (Fig. 5B). Together, these data demonstrate that miR-9 regulates inflammation production via the RIG-I signal pathway.

**NFκB is a target of miR-9**

Bioinformatics analysis has identified NFκB, which is a key immune sensor for the RLR innate immune response against EV71 infection, as a functional putative miR-9 target (Fig. 6A). A dual-luciferase reporter assay was conducted in six cell lines (293T, Vero, RD, HT-29, HeLa, and THP-1) to investigate direct binding between NFκB and miR-9. The data show that miR-9-mimic transfection decreased the luciferase activity of the reported fused with the NFκB 3’-UTR (Fig. 6B). Furthermore, we examined the NFκB expression in the six cell lines infected with EV71 and/or transfected with miR-9-mimic, using real-time PCR and western blotting. As shown in Fig. 6C,D, the NFκB expression was suppressed because of miR-9-mimic expression at both the protein and mRNA levels.

**miR-9 agomir administration ameliorates the EV71-induced inflammatory cytokine storm**

To further probe the mechanism of how miR-9 agomir administration attenuates EV71 replication and pathogenicity in an animal model, we performed real-time PCR to assess VP1 and cytokine levels. As shown in Fig. 7A, miR-9 was confirmed to be ectopically expressed by real-time PCR. Additionally, we found that VP1 expression was significantly reduced after miR-9 agomir administration, suggesting an antiviral effect of miR-9. Furthermore, the levels of the pro-inflammatory cytokines induced by EV71 were evaluated by real-time PCR experiment (Fig. 7B). As shown in Fig. 7C,D, robust expression of IL-1 and IFN-β was observed in muscle, lung, blood, and spleen tissues of EV71-infected mice. In contrast, the expression of these two cytokines was markedly inhibited with
Together, our data provide evidence that miR-9 confers an inhibitory effect on the EV71-induced cytokine storm and therefore ameliorates the damage caused by EV71.

**Discussion**

In this study, an inhibitory role of miR-9 in replication and pathogenicity of EV71 infection was observed both *in vitro* and *in vivo*. The expression pattern of viral EV71 protein was decreased by miR-9 treatment. Furthermore, we found that miR-9 was able to ameliorate the robust innate immune response against EV71 at different stages of infection by targeting the immune sensor NFκB and decreasing its expression.

Increasing evidence has demonstrated that excessive inflammatory signaling occurring during organ injury is one of the main pathogenic factors responsible for high mortality following EV71 infection [26–28]. NFκB is a signaling pathway that regulates many genes related to cell differentiation, proliferation, and innate immune response. In addition, via eliciting pro-inflammatory cytokine and type I IFN (IFN-β and IFN-α) expression, NFκB is important in the antiviral reactions of the host [29–31]. However, the 2C protein of EV71 suppresses NFκB activation, which increases the virus replication. Viral protein 2C suppresses the phosphorylation of IκBα and IKKβ via binding with their kinase domains, reducing NFκB activation, and promoting viral replication.
Fig. 7. Effect of miR-9 on EV71 replication and pathogenicity in mice. Mice were inoculated with EV71 or PBS as a negative control. Mice were then treated with miR-9 agomir. (A) Mice from the EV71 group and the NC group were sacrificed on day 4 or 5 postinoculation to determine miR-9 expression in different tissues of mice. Expression levels of VP1 (B), IL-1 (C), and IFN-β (D) in different tissues of EV71-infected mice were examined using real-time PCR. These assays have been performed three times. Data represent means ± SD. *P < 0.05; **P < 0.01; ***P < 0.001. The statistical test performed using Student’s t-test.
In our study, miR-9 administration resulted in deactivation and expression of NFkB while inhibiting EV71 replication. These results could be attributed to the robust pro-inflammatory cytokines, which are believed to contribute to EV71 pathogenicity, which were ameliorated by miR-9 expression, indicating that a moderate level of cytokines and interferon was maintained to limit the effect of EV71. However, the molecular mechanisms by which miR-9 controls VP1 expression and viral replication during EV71 infection still need further research to investigate the possibility of whether miR-9 inhibits inflammation and EV71 propagation separately.

The practical implication of miR-9 in evolution is suggested by its sequence conservation at the nucleotide level in different species rather than its varying expression patterns. Although the sequence of miR-9 is conserved, its expression profile differs significantly in various species. miR-9 is being extensively investigated in various biological processes: NPC proliferation and migration [33], neuronal differentiation [34], apoptotic cell death [35], brain function and neurodegeneration [36], and cancer [37]. Moreover, accumulating evidence suggests that miR-9 is required for replication of multiple of viruses. Dong et al. [38] indicated a novel function of miR-9 in influenza A virus infection and found that the influenza virus might hijack endogenous miR-9 for the viral life cycle. Tatro et al. [39] suggested that HIV infection induced elevated expression of miR-9, causing suppression of splice variants of KCNMA1, which may affect the release of neurotransmitters. Lai et al. reported that the nucleocapsid protein of human coronavirus OC43 causes activation of NFkB. This activation was the consequence of the nucleocapsid binding to RNA, specifically miR-9 (a negative NFkB modulator), as was found in this study [40]. Our study suggests that miR-9 is a negative mediator for EV71 replication in vitro and in vivo. Ectopic expression of miR-9 in cells resulted in inactivation of NFkB and ameliorated the excessive cytokine production, potentially lessening the organ injury induced by the cytokine storm during virus infection.

Conclusions
Our data imply that antiviral activity of miR-9 is related to regulation of the release of pro-inflammatory cytokines through RIG-I signal transduction via decreasing the activity and expression of NFkB. This study may provide new insights into EV71 infection suppression.

Acknowledgements
This work was supported by Research Fund of Jinan Maternity and Child Care Hospital.

Author contribution
In this work, BL and JZ conceived the study and designed the experiments, contributed to the data collection, performed the data analysis, and interpreted the results. BL wrote the manuscript and JZ contributed to the critical revision of article. Both authors read and approved the final manuscript.

Conflict of interest
The authors declare no conflict of interest.

References
1. Lui YL, Lin Z, Lee JJ, Chow VT, Poh CL and Tan EL (2013) Beta-actin variant is necessary for Enterovirus 71 replication. Biochem Biophys Res Commun 433, 607–610.
2. McMinn PC (2012) Recent advances in the molecular epidemiology and control of human enterovirus 71 infection. Curr Opin Virol 2, 199–205.
3. Patel KP and Bergelson JM (2009) Receptors identified for hand, foot and mouth virus. Nat Med 15, 728–729.
4. Wong SS, Yip CC, Lau SK and Yuen KY (2010) Human enterovirus 71 and hand, foot and mouth disease. Epidemiol Infect 138, 1071–1089.
5. Ho BC, Yu SL, Chen JJ, Chang SY, Yan BS, Hong QS, Singh S, Kao CL, Chen HY, Su KY et al. (2011) Enterovirus-induced miR-141 contributes to shutoff of host protein translation by targeting the translation initiation factor eIF4E. Cell Host Microbe 9, 58–69.
6. Huang HI, Weng KF and Shih SR (2012) Viral and host factors that contribute to pathogenicity of enterovirus 71. Future Microbiol 7, 467–479.
7. Wang Q, Zhang W, Zhang Y, Yan L, Wang S, Zhang J, Sun J, Chang Z and Wang Z (2014) Clinical features of severe cases of hand, foot and mouth disease with EV71 virus infection in China. Arch Med Sci 10, 510–516.
8. Chatproedprai S, Tempark T, Wanlapakorn N, Puenpa J, Wananukul S and Poovorawan Y (2015) Unusual skin manifestation of hand, foot and mouth disease associated with coxsackievirus A6: cases report. Springer plus 4, 362.
9. Shih SR, Ho MS, Lin KH, Wu SL, Chen YT, Wu CN, Lin TY, Chang LY, Tsao KC, Ning HC et al. (2000) Genetic analysis of enterovirus 71 isolated from fatal and non-fatal cases of hand, foot and mouth disease during an epidemic in Taiwan, 1998. Virus Res 68, 127–136.
MicroR-9-5p suppresses EV71 replication

B. Li and J. Zheng

10 Lin TY, Hsia SH, Huang YC, Wu CT and Chang LY (2003) Proinflammatory cytokine reactions in enterovirus 71 infections of the central nervous system. 
Clin Infect Dis 36, 269–274.

11 Graham AC, Hilmer KM, Zickovich JM and Obar JJ (2013) Inflammatory response of mast cells during influenza A virus infection is mediated by active infection and RIG-I signaling. 
J Immunol 190, 4676–4684.

12 Shinya K, Okamura T, Sueta S, Kasai N, Tanaka M, Ginting TE, Makino A, Eisfeld AJ and Kawaoya K (2011) Toll-like receptor pre-stimulation protects mice against lethal infection with highly pathogenic influenza viruses. 
Virology 408, 97.

13 Coates BM, Starichka KL, Ravindran N, Koch CM, Cheng Y, Davis JM, Shumaker DK and Ridge KM (2017) Inhibition of the NOD-Like Receptor Protein 3 Inflammasome Is Protective in Juvenile Influenza A Virus Infection. 
Front Immunol 8, 782.

14 Seth RB, Sun L, Ea CK and Chen ZJ (2005) Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. 
Cell 122, 669–682.

15 Kido H (2015) Influenza virus pathogenicity regulated by host cellular proteases, cytokines and metabolites, and its therapeutic options. 
Proc Jpn Acad Ser B Phys Biol Sci 91, 351–368.

16 Lee RC, Feinbaum RL & Ambros V. (1993) The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. 
Cell 75: 843–854.

17 Yang Y, Yang L, Liang X and Zhu G (2015) MicroRNA-155 promotes atherosclerosis inflammation via targeting SOCS1. 
Cell Physiol Biochem 36, 1371–1381.

18 Xiong Y, Qiu J, Li C, Qiu Y, Guo L, Liu Y, Tan J, Li Y, Wu G, Wang L et al. (2018) Fortunellin-induced modulation of phosphorytase and tensin homolog by MicroRNA-374a decreases inflammation and maintains intestinal barrier function in colitis. 
Front Immunol 9, 83.

19 Gu W, Zhan H, Zhou XY, Yao L, Yan M, Chen A, Liu J, Ren X, Zhang X, Liu XJ et al. (2017) MicroRNA-22 regulates inflammation and angiogenesis via targeting VE-cadherin. 
FEBS Lett 591, 513–526.

20 Johansson K, Malmhall C, Ramos-Ramirez P and Radinger M (2017) MicroRNA-155 is a critical regulator of type 2 innate lymphoid cells and IL-33 signaling in experimental models of allergic airway inflammation. 
J Allergy Clin Immunol 139 (1007–1016), e9.

21 Karlsen TA, de Souza GA, Odegaard B, Engebretsen L and Brinchmann JE (2016) microRNA-140 inhibits inflammation and stimulates chondrogenesis in a model of interleukin 1beta-induced osteoarthritis. 
Mol Ther Nucleic Acids 5, e373.

22 Lv F, Huang Y, Lv W, Yang L, Li F, Fan J and Sun J (2017) MicroRNA-146a ameliorates inflammation via TRAF6/NF-kappaB pathway in intervertebral disc cells. 
Med Sci Monit 23, 659–664.

23 Hu Y, Song J, Liu L, Li J, Tang B, Wang J, Zhang X, Zhang Y, Wang L, Liao Y et al. (2016) Different microRNA alterations contribute to diverse outcomes following EV71 and CA16 infections: Insights from high-throughput sequencing in rhesus monkey peripheral blood mononuclear cells. 
Int J Biochem Cell Biol 81, 20–31.

24 Song J, Hu Y, Li J, Zheng H, Wang J, Guo L, Ning R, Li H, Yang Z, Fan H et al. (2017) Different microRNA profiles reveal the diverse outcomes induced by EV71 and CA16 infection in human umbilical vein endothelial cells using high-throughput sequencing. 
PloS ONE 12, e0177657.

25 Wen BP, Dai HJ, Yang YH, Zhuang Y and Sheng R (2013) MicroRNA-23b inhibits enterovirus 71 replication through downregulation of EV71 VPI protein. 
Interimmunology 56, 195–200.

26 Lui YL, Tan TL, Woo WH, Timms P, Hafner LM, Tan KH and Tan EL (2014) Enterovirus71 (EV71) utilise host microRNAs to mediate host immune system enhancing survival during infection. 
PloS ONE 9, e102997.

27 Fu Y, Zhang L, Zhang F, Tang T, Zhou Q, Feng C, Jin Y and Wu Z (2017) Exosome-mediated mir-146a transfer suppresses type I interferon response and facilitates EV71 infection. 
PLoS Pathog 13, e1006611.

28 Pathinayake PS, Hsu AC and Wark PA (2015) Innate immunity and immune evasion by enterovirus 71. 
Viruses 7, 6613–6630.

29 Baeuerele PA and Baltimore D (1996) NF-kappaB: ten years after. 
Cell 87, 13–20.

30 Pahl HL (1999) Activators and target genes of Rel/NF-kappaB transcription factors. 
Oncogene 18, 6853–6866.

31 Hiscott J, Nguyen TL, Arguello M, Nakhaei P and Paz S (2006) Manipulation of the nuclear factor-kappaB pathway and the innate immune response by viruses. 
Oncogene 25, 6844–6867.

32 Zheng Z, Li H, Zhang Z, Meng J, Mao D, Bai B, Lu B, Mao P, Hu Q and Wang H (2011) Enterovirus 71 2C protein inhibits TNF-alpha-mediated activation of NF-kappaB by suppressing IkappaB kinase beta phosphorylation. 
J Immunol 187, 2202–2212.

33 Shibata M, Kurokawa D, Nakao H, Ohmura T and Aizawa S (2008) MicroRNA-9 modulates Cajal-Retzius cell differentiation by suppressing Foxg1 expression in mouse medial pallium. 
J Neurosci 28, 10415–10421.

34 Leucht C, Stigloher C, Wizenmann A, Klafke R, Folchert A and Bally-Cuif L (2008) MicroRNA-9 directs late organizer activity of the midbrain-hindbrain boundary. 
Nat Neurosci 11, 641–648.

35 Delaloy C, Liu L, Lee JA, Su H, Shen F, Yang GY, Young WL, Ivey KN and Gao FB (2010) MicroRNA-9
coordinates proliferation and migration of human embryonic stem cell-derived neural progenitors. *Cell Stem Cell* **6**, 323–335.

36 Pietrzykowski AZ, Friesen RM, Martin GE, Puig SI, Nowak CL, Wynne PM, Siegelmann HT and Treisman SN (2008) Posttranscriptional regulation of BK channel splice variant stability by miR-9 underlies neuroadaptation to alcohol. *Neuron* **59**, 274–287.

37 Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, Teruya-Feldstein J, Reinhardt F, Onder TT, Valastyan S et al. (2010) miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. *Nat Cell Biol* **12**, 247–256.

38 Dong C, Sun X, Guan Z, Zhang M and Duan M (2017) Modulation of influenza A virus replication by microRNA-9 through targeting MCPIP1. *J Med Virol* **89**, 41–48.

39 Tatro ET, Hefler S, Shumaker-Armstrong S, Soontornniyomkij B, Yang M, Yermanos A, Wren N, Moore DJ and Achim CL (2013) Modulation of BK channel by MicroRNA-9 in neurons after exposure to HIV and methamphetamine. *J Neuroimmune Pharmacol* **8**, 1210–1223.

40 Lai FW, Stephenson KB, Mahony J and Lichty BD (2014) Human coronavirus OC43 nucleocapsid protein binds microRNA 9 and potentiates NF-kappaB activation. *J Virol* **88**, 54–65.